medigraphic.com

2013, Number 2

<< Back Next >>

Enf Infec Microbiol 2013; 33 (2)

Campylobacter jejuni: ¿A forgotten bacteria? Its situation in Mexico

Hernández CC, Aguilera AMG, Castro EG

Language: Spanish
References: 60
Page: 77-84
PDF size: 190.41 Kb.


ABSTRACT

Campylobacter jejuni is one of the causative agents of gastroenteritis in humans, and it is one of the bacteria related mainly with the Guillain-Barré syndrome. It is considered a diners microorganism of poultry and other animals. In Mexico, the search for C. jejuni and other species of the Campylobacter genus is not performed routinely in clinical laboratories; however, it is important to perform this search because, aside from causing gastroenteritis, this bacteria is involved in important autoimmune diseases that affect people of all ages. Knowing the actual situation of C. jejuni in our country will help to understand why it is an apparently forgotten bacterium, since we know its isolation is much higher in developed countries than in underdeveloped ones. For this reason, its routine search should not be abandoned, because it would probably yield relevant results on the presence and isolation of this microorganism in the Mexican population and in those animals meant for human consumption, which are the main source of contamination. Based on the aforementioned, the present review is aimed at covering the current information about this microorganism, placing emphasis on the diagnostic methods used for its identification, the most relevant studies performed in Mexico, and in other countries on the diseases caused by this bacteria, the state of vaccine development against it, as well as the treatment, management, and prevention of campilobacteriosis.


REFERENCES

  1. Escamilla AE. “Géneros: Campylobacter, Arcobacter y Helicobacter”. En Lugo de la Fuente G. Bacteriología Médica. Ed. Cuellar, México. 3a edición, 2005: 57-62.

  2. Zhang MJ, Xiao D, Zhao F, Gu YX, Meng FL, He LH, et al. “Comparative proteomic analysis of Campylobacter jejuni cultured at 37C and 42C”. J Infect Dis 2009; 62: 356-361.

  3. Sebald M, Véron M. “Tenuer en bases de l’ADN et classification des vibrions”. Ann Inst Pasteur 1963; 105: 897-910.

  4. Véron M, Chatelain R. “Taxonomic study of the genus Campylobacter Sebald and Véron and designation of the neotype strain for the type species, Campylobacter fetus (Smith and Taylor) Sebald and Véron”. Int J Syst Bacteriol 1973; 23: 122-134.

  5. Man SM. “The clinical importance of emerging Campylobacter species”. Nat Rev Gastroenterol Hepatol 2011; 8: 669-685.

  6. Stephen LWO. “Taxonomy, phylogeny and methods for the identification of Campylobacter Species”. En Ketley JM, Konkel ME. (Eds.) Campylobacter. Molecular and cellular biology. Reino Unido, Horizon Bioscience, 2005: 13-42.

  7. Young KT, Davis LM, DiRita VJ. “Campylobacter jejuni: molecular biology and pathogenesis”. Nature Rev. Microbiol 2007; 5: 665-679.

  8. Cervantes GE, Cravioto QA. “Campylobacter y enfermedades asociadas”. Rev Fac Med UNAM 2007; 50: 31-35.

  9. http://www.midiatecavipec.com/avicultura/avicultura021204. htm

  10. Schrotz-King P, Prokhorova TA, Nielsen PN, Crawford JS, Morsczeck C. “Campylobacter jejuni proteomics for new travellers’ diarrhea vaccines”. Travel Med Infect Dis 2007; 5: 106-109.

  11. Melano CE, Carrillo ME, Gulías HA. “Síndrome de Guillain- Barré en el anciano: un estudio restrospectivo”. Arch Neurocien 2004; 9: 76-79.

  12. Gamarra GNS, Rosciani FC, Sosa FA. “Una revisión: Síndrome de Guillain-Barré”. Rev Posgrado VIa Cátedra de Medicina 2010; 199: 22-26.

  13. Mandell GL, Bennett JE, Dolin R. “Campylobacter jejuni y especies relacionadas”. En Mandell, Douglas y Bennett. (Eds.) Enfermedades infecciosas. Principios y Prácticas, vol. 2. España, Elsevier, 2006: 2551-2553.

  14. Pei Z, Blaser MJ. “PEB1, the major cell-binding factor of Campylobacter jejuni, is a homolog of the binding component in Gram-negative nutrient transport systems”. J Biol Chem 1993; 25: 18717-18725.

  15. Poly F, Guerry P. “Pathogenesis of Campylobacter”. Current Opinion Gastroenterology 2008; 27-31.

  16. Haddad N, Marce C, Magras C, Cappelier JM. “An overview of methods used to clarify pathogenesis mechanisms of Campylobacter jejuni”. J Food Prot 2010; 73: 786-802.

  17. Kopecko DJ, Hu L, Zaal KJ. “Campylobacter jejuni microtubule dependent invasion”. Trends Microbiol 2001; 9: 389-396.

  18. Fouts DE, Mongodin EE, Nelson KE. “Campylobacter pathogenomics: genomes and beyond”. En Pallen MJ, Nelson KE, Preston GM. (Eds.) Bacterial pathogenomics. Washington DC, ASM Press, 2007: 162-166.

  19. Acosta MI, Cañiza MJ, Romano MF, Araujo EM. “Síndrome de Guillain-Barré”. Rev Posgrado VIa Cátedra de Medicina 2007; 168: 15-18.

  20. Martiny D, Dediste A, Debruyne L, Vlaes L, Haddou NB, Vandamme P, et al. “Accuracy of the API Campy system, the Vitek 2 Neisseria-Haemophilus card and matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the identification of Campylobacter and related organisms”. Clin Microbiol Infect 2011; 17: 1001- 1006.

  21. Nachamkin I. “Campylobacter and Arcobacter”. En Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH. Manual of clinical microbiology, vol. 1, 8a ed. Washington DC, ASM Press, 2003: 908.

  22. http://www.cdc.gov/ncidod/dbmd/gss/publications/documents/ Argentina-LevelI/ManualProcedimientos_Campylobacter. pdf

  23. http://www.bvsops.org.uy/pdf/campylobacter.pdf

  24. Al Amri A, Senok AC, Yusuf IA, Ali E, Al-Mahmeed, Botta GA. “Multiplex PCR for direct identification of Campylobacter spp. in human and chicken stools”. J Med Microbiol 2007; 56: 1350-1355.

  25. Persson S, Olsen KE P. “Multiplex PCR for identification of Campylobacter coli and Campylobacter jejuni from pure cultures and directly on stool samples”. J Med Microbiol 2005; 54: 1043-1047.

  26. Wang G, Clark CG, Taylor TM, Pucknell C, Barton C, Price L, et al. “Colony multiplex PCR assay for identification and differentiation of Campylobacter jejuni, C. coli, C. lari, C. upsaliensis, and C. fetus subsp. fetus.).” J Clin Microbiol 2002; 40: 4744-4747.

  27. Gómez-Duarte O, Bai J, Newel E. “Detection of E. coli, Salmonella spp., Shigella spp., Yersinia enterocolitica, Vibrio cholerae and Campylobacter spp. Enteropathogens by three-reaction multiplex PCR”. Diagn Microbiol Infect Dis 2009; 63:1-9.

  28. Prokhorova TA, Nielsen PN, Petersen J, Kofoed T, Crawford JS, Morsczeck C, et al. “Novel surface polypeptides of Campylobacter jejuni as traveller’s diarrhoea vaccine candidates discovered by proteomics”. Vaccine 2006; 24: 6446-6455.

  29. Scott NE, Cordwell SJ. “Campylobacter proteomics: guidelines, challenges and future perspectives”. Expert Rev Proteomics 2009; 6: 61-74.

  30. Sánchez de la Barquera RM, Herrera BIF. “Diarrea por Campylobacter”. En Romero CR, Herrera BIF. (Eds.) Síndrome diarreico infeccioso. México-España. Ed. Médica Panamericana, 2002: 204-205.

  31. Baker C. “Campylobacter, infecciones”. En Baker C. Red Book: Atlas de enfermedades infecciosas en pediatría. Argentina, Ed. Médica Panamericana, 2009: 32-33.

  32. Ruiz-Palacios GM. “The health burden of Campylobacter infection and the impact of antimicrobial resistance: playing chicken”. Clin Infect Dis 2007; 44: 701-703.

  33. Villa NA, Okhuysen PC, Flores-Figueroa J, Zhi-Dong J, Belkind- Gerson J, Paredes M, et al. “Campylobacter jejuni is not an important pathogen as a cause of diarrhea in U.S. travelers to Mexico”. J Travel Med 2011; 18: 56-58.

  34. Nielsen LN, Luijkx TA, Vegge CS, Johnsen CK, Nuijten P, Wren BW, et al. “Identification of immunogenic and virulence- associated Campylobacter jejuni proteins”. Clin Vaccine Immunol 2012; 19: 113-119.

  35. Guerry P, Poly F, Riddle M, Maue AC, Chen YH, Monteiro MA. “Campylobacter polysaccharide capsules: virulence and vaccines”. Front Cell Infect Microbiol 2012; 2: 1-11. Monteiro MA, Baqar S, Hall ER, Chen YH, Porter CK,

  36. Bentzel DE, et al. “Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni”. Infect Immun 2009; 77: 1128-1136.

  37. Burrough ER, Sahin O, Plummer PJ, DiVerde KD, Zhang Q, Yaeger MJ. “Comparison of two commercial ovine Campylobacter vaccines and an experimental bacterin in guinea pigs inoculated with Campylobacter jejuni”. Am J Vet Res 2011; 72: 799-805.

  38. http://www.sani.com.ar/producto.php?id_producto=3706

  39. http://acebiosciences.com/

  40. http:/ /pharmalicensing.com/public/companies/ view/3789/ace-biosciences

  41. Hobb RI, Fields JA, Burns CM, Thompson SA. “Evaluation of procedures for outer membrane isolation from Campylobacter jejuni”. Microbiology 2009; 155: 979-988.

  42. Jagusztyn-Krynicka EK, Laniewski P, Wyszy ska A. “Update on Campylobacter jejuni vaccine development for preventing human campilobacteriosis”. Expert Rev Vaccines 2009; 8: 625-645.

  43. Cordwell SJ, Len AC, Touma RG, Scott NE, Falconer L, Jones D, et al. “Identification of membrane-associated proteins from Campylobacter jejuni strains using complementary proteomics technologies”. Proteomics 2008; 1: 122-139.

  44. Seal BS, Hiett KL, Kuntz RL, Woolsey R, Schegg KM, Ard M, et al. “Proteomic analyses of a robust versus a poor chicken gastrointestinal colonizing isolate of Campylobacter jejuni”. J Proteome Res 2007; 12: 4582-4591.

  45. Asbury AK. “Nuevos conceptos sobre el síndrome de Guillain-Barré”. J Child Neurol 2000; 15: 183-191.

  46. http://www.foodpoisonjournal.com

  47. Ailes E, Demma L, Hurd S, Hatch J, Jones TF, Vugia D, et al. “Continued decline in the incidence of Campylobacter infections, FoodNet 1996-2006”. Foodborne Pathog Dis 2008; 5: 329-337.

  48. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. “Human campylobacteriosis in developing countries”. Emerg Infect Dis 2002; 8: 237-244.

  49. Nachamkin I, Arzarte Barbosa P, Ung H, Lobato C, González Rivera A, Rodríguez P, et al. “Patterns of Guillain-Barre syndrome in children: results from a Mexican population”. Neurology 2007; 69: 1665-1671.

  50. González RA, Chico AP, Arzate-Barbosa P, Rodríguez-Pinto M, Mckhann-Guy, et al. “Epidemiología del síndrome de Guillain-Barré asociado a Campylobacter jejuni en el INP”. Acta Pediatr Mex 2006; 27: 300-303.

  51. Rees JH, Soudain SE, Gregson NA, Hughes RAC. “Campylobacter jejuni infection and Guillain-Barré syndrome”. N Engl J Med 1995; 333: 1374-1379.

  52. Talan J. “Campylobacter infection implicated in Guillain-Barré syndrome in Mexico”. Neurology 2007; 7: 16-18.

  53. http://barfblog.foodsafety.ksu.edublog/149602/11/07/ 25/guillain-barre-syndrome-victims-rise-arizona-mexico- campylobacter-outbreak

  54. Moore EJ, Corcoran D, Dooley JSG, Fanning S, Lucey B, Matsuda M, et al. “Campylobacter”. Vet Res 2005; 36: 351-382.

  55. Gutiérrez CAD, Paasch MLH, Calderón ANL. “Salmonelosis y campilobacteriosis, las zoonosis emergentes de mayor expansión en el mundo”. Vet Mex 2008; 39: 81-90.

  56. Quiñones Ramírez EI, Vázquez Salinas C, Rodas Suárez OR, Ramos Flores MO, Rodríguez Montaño R. “Frequency of isolation of Campylobacter from roasted chicken samples from Mexico City”. J Food Prot 2000; 63: 117-119.

  57. Carvalho ACT, Ruiz Palacio G, Ramos Cervantes P, Cervantes LE, Jiang X, Pickering LK. “Molecular Characterization of invasive and noninvasive Campylobacter jejuni and Campylobacter coli isolates”. J Clin Microbiol 2001; 39: 1353-1359.

  58. Ruiz Palacios GM, Cervantes LE, Ramos P, Chávez Munguía B, Newburg DS. “Campylobacter jejuni binds intestinal H (O) antigen (Fucα1, 2Galβ1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection”. J Biol Chem 2003; 270: 14112-14120.

  59. http://www.cdc.gov/nczved/divisions/dfbmd/diseases/ campylobacter/#control

  60. http://www.wattagnet.com/Peligros_relacionados_con_la_ presencia_de_Campylobacter_en_la_producci%C3%B3n_ de_pollo_y_huevo.html




2020     |     www.medigraphic.com